Do the new PCPT findings make you less likely to recommend finasteride for PCa?

Share this article:

After 18 months of follow-up of patients in the Prostate Cancer Prevention Trial (PCPT), Ian M. Thompson, Jr. MD, and colleagues found that finasteride decreased the risk of prostate cancer (PCa) by about a one third, but it had no effect on overall survival or survival after the diagnosis of PCa, according to a report in the New England Journal of Medicine (2013;369:603-610). 

In an editorial accompanying the report, Michael LeFevre, MD, wrote that the safest conclusion one can draw about the use of finasteride for PCa prevention “is that it has no short- or long-term effect on all-cause mortality, so we cannot recommend its use to prolong life.” 

Renal & Urology News invites urologists to answer the following online poll question.


Share this article:
You must be a registered member of RUN to post a comment.

Sign Up for Free e-newsletters

More in Physician Polls

How much influence does the U.S. Surgeon General have on the nation's public health?

How much influence does the U.S. Surgeon General ...

The U.S. Surgeon General is the operational head of about 6,800 uniformed health officers.

During your career, have you ever rendered in-flight medical assistance?

During your career, have you ever rendered in-flight ...

It is inevitable that some passengers will become ill during a flight.

How do you feel about on-call emergency department coverage?

How do you feel about on-call emergency department ...

The nation's community hospitals are facing increasing problems obtaining emergency on-call coverage.